Impact of Sustained Release d-Amphetamine on Choice Between Cocaine and a Non-Drug Reinforcer


Cocaine-use disorders continue to be a significant public health concern, yet no effective medications have been identified. The goal of this study is to establish a research platform for the development of medications for treatment of cocaine abuse and dependence. This study will incorporate choice self-administration procedures between drug and a non-drug alternative reinforcer presented during maintenance on d-amphetamine, which has been previously shown to reduce cocaine use.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Basic Science
    • Masking: Double (Participant, Outcomes Assessor)
  • Study Primary Completion Date: April 5, 2018


  • Drug: Cocaine
  • Drug: Sustained Release d-Amphetamine

Arms, Groups and Cohorts

  • Experimental: Active Treatment
    • Cocaine choice during d-amphetamine maintenance
  • Placebo Comparator: Placebo Treatment
    • Cocaine choice during placebo maintenance

Clinical Trial Outcome Measures

Primary Measures

  • The Number of Times Cocaine Was Selected in the Presence of a Monetary Reward Alternative
    • Time Frame: 9 choice trials per cocaine dose level with each trial separated by 30 minutes
    • The reinforcing effects of cocaine were determined using a modified progressive ratio procedure (Lile et al., 2016) in which subjects made 9 choices between each available cocaine dose and money (US$6.00). Reinforcing effects are measured for each cocaine dose during both d-amphetamine and placebo maintenance.

Participating in This Clinical Trial

Inclusion Criteria

  • Recent cocaine use, otherwise healthy Exclusion Criteria:

  • Laboratory results outside of clinically acceptable ranges, history of or current serious physical or psychiatric disease

Gender Eligibility: All

Minimum Age: 21 Years

Maximum Age: 45 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Joshua A. Lile, Ph.D.
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: Joshua A. Lile, Ph.D., Joshua A. Lile, Ph.D., Associate Professor of Behavioral Science – University of Kentucky

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.